7443-02-9 Usage
Uses
Used in Organic Synthesis:
(1,3-dioxo-2-phenyl-2,3-dihydro-1H-inden-2-yl)acetic acid is used as a synthetic intermediate for the creation of more complex organic molecules. Its unique structure allows it to serve as a building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (1,3-dioxo-2-phenyl-2,3-dihydro-1H-inden-2-yl)acetic acid is used as a potential active pharmaceutical ingredient (API). Its complex molecular structure may offer novel mechanisms of action or binding affinities, making it a candidate for the development of new drugs.
Used in Materials Science:
(1,3-dioxo-2-phenyl-2,3-dihydro-1H-inden-2-yl)acetic acid may also find applications in materials science, where its unique properties could be leveraged to develop new materials with specific characteristics, such as improved stability, reactivity, or selectivity in various chemical processes.
Further research is essential to explore the full potential of (1,3-dioxo-2-phenyl-2,3-dihydro-1H-inden-2-yl)acetic acid and to determine its suitability for these and other applications.
Check Digit Verification of cas no
The CAS Registry Mumber 7443-02-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,4,4 and 3 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 7443-02:
(6*7)+(5*4)+(4*4)+(3*3)+(2*0)+(1*2)=89
89 % 10 = 9
So 7443-02-9 is a valid CAS Registry Number.
7443-02-9Relevant academic research and scientific papers
Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof
-
Page/Page column 24, (2008/06/13)
Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is -A1QA2-; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(═O)NR6—. Y is selected from hydrogen, C1-4alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are independently selected from a bond, C1-3alkylene, or C1-3alkenylene, and R1-R11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.
